Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report. (2021)

• Record Type: Journal Article
• Authors: Abe, Masaya; Fujii, Nobuharu; Mizuhara, Kentaro; Urata, Tomohiro; Sumii, Yuichi; Fujiwara, Yuki; Seike, Keisuke; Sando, Yasuhisa; Nakamura, Makoto; Fujii, Keiko; Saeki, Kyosuke; Meguri, Yusuke; Asada, Noboru; Ennishi, Daisuke; Nishimori, Hisakazu; Matsuoka, Ken-ichi; Maeda, Yoshinobu
• Is Part Of: Leukemia research reports. Volume 15(2021)
• Publication Date: 2021
• Subjects: Acute lymphoblastic leukemia -- Inotuzumab ozogamicin -- Sinusoidal obstruction syndrome -- Hematopoietic stem cell transplantation -- Posttransplant cyclophosphamide; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2021.100241
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.